Complete DNA analysis for young adults with cancer
KWF finances the expansion of the infrastructure for cancer research in young adults with almost 4.5 million euros. These are young people aged 18 to 39, also known as AYAs: Adolescents and Young Adults. With this grant, Hartwig Medical Foundation will use the latest techniques to visualize the complete DNA of the tumor for 1,000 patients over the next four years. This means that the treatment can be better attuned to the specific tumor characteristics of each patient.
GENAYA
The genetic information and treatment data are stored with the patient’s consent in a globally unique database and made available for scientific research. In this way, not only these 1,000 patients will benefit from the research, but also the patients in the future. The project named GENAYA (a national database of GENome data of Adolescent and Young Adult cancers) builds on an infrastructure already funded by KWF; COMPRAYA. Hartwig Medical Foundation will provide diagnostic DNA analysis based on whole genome sequencing for GENAYA. Thanks to the grant from KWF, the complete DNA analysis are also made available to AYA patients in non-academic centers.
Hartwig Medical Foundation
Hartwig Medical is a not-for-profit foundation. The foundation aims to improve care for patients with cancer. It does this by advancing cancer research and conducting complete DNA analysis in cancer patients. This should contribute to ensuring that every cancer patient receives the treatment that best suits her or him.
More information
- Complete DNA test
- Hartwig Medical database
- Publications with data from Hartwig Medical database
All news
Also read
DataNexus connects clinical and genomic data
DataNexus is a project initiated by the Netherlands Cancer Institute–Antoni van Leeuwenhoek (NKI-AvL) to improve data availability by integrating clinical …
Without structured real world data, it remains guesswork who truly benefits
The decision by the Dutch National Health Care Institute (Zorginstituut Nederland, ZiNL) to reassess the reimbursement of expensive medicines after …
New CPoC grant awarded: GLOW – GLioblastoma targeted treatment Option maximisation by WGS
Oncode Institute has announced that the 13th grant within the Clinical Proof of Concept programme has been awarded. Oncode Investigator …
I know how important knowledge of hereditary predisposition to cancer can be. This is why I think it is so important that comprehensive patient reports include precisely that carrier information, if the patient wishes to be informed of it.